Surgery Partners director buys 10,000 shares at $14.35

Surgery Partners, Inc. (SGRY) director Teresa DeLuca reported an open-market purchase of company stock.

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) director Teresa DeLuca reported an open-market purchase of company stock. On 2026-08-18 she purchased 10,000 shares of common stock at a weighted average price of $14.35 per share, and now directly holds 66,843 shares of Surgery Partners common stock.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider DeLuca Teresa

Role Director

Bought 10,000 shs ($144K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	10,000	$14.35	$144K

Holdings After Transaction: Common Stock — 66,843 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

Key Figures

Shares purchased: 10,000 shares Weighted average purchase price: $14.35 per share Shares owned after transaction: 66,843 shares

3 metrics

Shares purchased 10,000 shares Common Stock acquired on 2026-08-18 in open-market or private transaction

Weighted average purchase price $14.35 per share Price for the 10,000-share Common Stock purchase on 2026-08-18

Shares owned after transaction 66,843 shares Total direct holdings of Common Stock following the reported purchase

Key Terms

Form 4, weighted average price, open market or private transaction

3 terms

Form 4 regulatory

"reported an open-market purchase of company stock on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction code description: Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SGRY director Teresa DeLuca report?

Director Teresa DeLuca reported purchasing 10,000 shares of Surgery Partners common stock on 2026-08-18. The transaction was coded as a "P" open-market or private purchase on Form 4.

At what price did Teresa DeLuca buy SGRY stock in this Form 4?

She purchased the shares at a weighted average price of $14.35 per share. A footnote states she can provide full details of the number of shares bought at each separate price upon request.

How many SGRY shares does Teresa DeLuca own after this transaction?

Following the reported purchase, Teresa DeLuca directly owns 66,843 shares of Surgery Partners common stock. This figure reflects her post-transaction direct holdings as disclosed in the Form 4.

Was Teresa DeLuca’s SGRY trade under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and no footnote describes a trading plan. The transaction is therefore not identified as made under a Rule 10b5-1 plan in this report.

What type of security did Teresa DeLuca acquire in SGRY?

She acquired Common Stock of Surgery Partners, Inc. The Form 4 reports a non-derivative transaction, meaning it involved direct share purchases rather than options or other derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:18 PM EDT Accepted by SEC EDGAR 08/19/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLuca Teresa

(Last) (First) (Middle)

C/O SURGERY PARTNERS, INC.

340 SEVEN SPRINGS WAY, SUITE 600

(Street)

BRENTWOOD TENNESSEE 37027

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		P		10,000	A	$14.35(1)	66,843	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Jennifer Baldock, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)